Investigators from the University of Georgia, Science and Behavior Program reviewed the analgesic properties of cannabis and cannabis-based agonists in over three dozen preclinical and clinical trials.
Researchers reported, “During the last two decades, a large number of research articles have demonstrated the efficacy of cannabinoids and modulators … in suppressing neuropathic pain.”
They concluded: “Clinical studies largely reaffirm that cannabinoids show efficacy in suppressing diverse neuropathic pain states in human. … The present review suggests that cannabinoids show promise for treatment of neuropathic pain in humans either alone or as an add-on to other therapeutic agents.”
Neuropathy is a debilitating form of chronic pain resulting primarily from nerve injury. Patients suffering from neuropathic pain seldom respond favorably to conventional analgesics, including opiates and non-steroidal anti-inflammatory drugs (NSAIDS).
For more information, please contact Paul Armentano, NORML Deputy Director, at: email@example.com. Full text of the study, “Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside,” appears in Neurotherapeutics. Additional information on cannabis and neuropathy appears in NORML’s booklet Emerging Clinical Applications for Cannabis,” available online at: http://www.norml.org//index.cfm?Group_ID=7786.